Skip to main content
Erschienen in: Der Pathologe 3/2015

01.05.2015 | Schwerpunkt: Neuroendokrine Tumoren

Was ist neu in der Pathologie neuroendokriner Tumoren des Pankreas?

verfasst von: Prof. Dr. P. Komminoth, Prof. Dr. A. Perren

Erschienen in: Die Pathologie | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Diagnostik neuroendokriner Neoplasien des Pankreas (PanNEN) hat in den letzten Jahren v. a. im Bereich der WHO-Klassifikation, der TNM-Einteilung sowie der Gradierung Veränderungen erfahren. Zudem wurden einzelne neue diagnostische sowie prädiktive immunhistochemische Marker eingeführt. Die meisten Fortschritte wurden auf der Ebene der molekularen Pathogenese von PanNEN erzielt. Mittels „next generation sequencing“ wurden der „mammalian target of rapamycin (mTOR) pathway“, Hypoxie, aber auch epigenetische Veränderungen als wichtige tumorigene Mechanismen identifiziert. Im vorliegenden Artikel werden die wichtigsten Entwicklungen in der morphologischen und immunhistochemischen Diagnostik von PanNEN und deren molekularer Hintergrund beleuchtet.
Literatur
1.
Zurück zum Zitat Albers MB, Maurer E, Kloppel G et al (2014) Pancreatic polypeptide-rich islets in the posterior portion of the pancreatic head–a tumor mimic in somatostatin receptor scintigraphy. Pancreas 43:648–650CrossRefPubMed Albers MB, Maurer E, Kloppel G et al (2014) Pancreatic polypeptide-rich islets in the posterior portion of the pancreatic head–a tumor mimic in somatostatin receptor scintigraphy. Pancreas 43:648–650CrossRefPubMed
2.
Zurück zum Zitat Alkatout I, Friemel J, Sitek B et al (2015) Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol 28:69–79CrossRefPubMed Alkatout I, Friemel J, Sitek B et al (2015) Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol 28:69–79CrossRefPubMed
3.
Zurück zum Zitat Basturk O, Tang L, Hruban RH et al (2014) Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 38:437–447CrossRefPubMedCentralPubMed Basturk O, Tang L, Hruban RH et al (2014) Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 38:437–447CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Cao Y, Gao Z, Li L et al (2013) Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 4:2810PubMed Cao Y, Gao Z, Li L et al (2013) Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 4:2810PubMed
5.
Zurück zum Zitat Carlinfante G, Baccarini P, Berretti D et al (2014) Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. Virchows Arch 465:49–55CrossRefPubMed Carlinfante G, Baccarini P, Berretti D et al (2014) Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. Virchows Arch 465:49–55CrossRefPubMed
6.
Zurück zum Zitat Couvelard A, O’toole D, Turley H et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94–101CrossRefPubMedCentralPubMed Couvelard A, O’toole D, Turley H et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94–101CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199–1203CrossRefPubMedCentralPubMed Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199–1203CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Klimstra DS, Fukushima N, Hruban RH et al (2010) Diagnostic algorithms for tumours of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the digestive system. IARC, Lyon Klimstra DS, Fukushima N, Hruban RH et al (2010) Diagnostic algorithms for tumours of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the digestive system. IARC, Lyon
11.
Zurück zum Zitat Kloppel G, Anlauf M, Perren A et al (2014) Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol 25:181–185CrossRefPubMed Kloppel G, Anlauf M, Perren A et al (2014) Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas. Endocr Pathol 25:181–185CrossRefPubMed
12.
Zurück zum Zitat Kloppel G, Anlauf M, Raffel A et al (2008) Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 39:3–8CrossRefPubMed Kloppel G, Anlauf M, Raffel A et al (2008) Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 39:3–8CrossRefPubMed
13.
Zurück zum Zitat Kloppel G, Rindi G, Perren A et al (2010) The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment. Pathologe 31:353–354CrossRefPubMed Kloppel G, Rindi G, Perren A et al (2010) The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment. Pathologe 31:353–354CrossRefPubMed
14.
Zurück zum Zitat Korner M, Waser B, Schonbrunn A et al (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242–252CrossRefPubMedCentralPubMed Korner M, Waser B, Schonbrunn A et al (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242–252CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Luttges J (2011) What’s new? The 2010 WHO classification for tumours of the pancreas. Pathologe 32 (Suppl 2):332–336CrossRefPubMed Luttges J (2011) What’s new? The 2010 WHO classification for tumours of the pancreas. Pathologe 32 (Suppl 2):332–336CrossRefPubMed
16.
Zurück zum Zitat Marinoni I, Kurrer AS, Vassella E et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146:453–460 e455 Marinoni I, Kurrer AS, Vassella E et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146:453–460 e455
17.
Zurück zum Zitat Munding J, Luttges J, Esposito I et al (2014) Update of the S3 guidelines for pancreatic cancer. What is new for pathologists? Pathologe 35:509–518 (quiz 518–520)CrossRefPubMed Munding J, Luttges J, Esposito I et al (2014) Update of the S3 guidelines for pancreatic cancer. What is new for pathologists? Pathologe 35:509–518 (quiz 518–520)CrossRefPubMed
18.
Zurück zum Zitat Oberg K (2012) Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 24:433–440CrossRefPubMed Oberg K (2012) Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 24:433–440CrossRefPubMed
19.
Zurück zum Zitat Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRefPubMed Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777CrossRefPubMed
20.
Zurück zum Zitat Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedCentralPubMed Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762CrossRefPubMed Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762CrossRefPubMed
22.
Zurück zum Zitat Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRefPubMed Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833CrossRefPubMed
23.
Zurück zum Zitat Schmitt AM, Anlauf M, Rousson V et al (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31:1677–1682CrossRefPubMed Schmitt AM, Anlauf M, Rousson V et al (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31:1677–1682CrossRefPubMed
24.
Zurück zum Zitat Schmitt AM, Riniker F, Anlauf M et al (2008) Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32:420–425CrossRefPubMed Schmitt AM, Riniker F, Anlauf M et al (2008) Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32:420–425CrossRefPubMed
25.
Zurück zum Zitat Schmitt AM, Schmid S, Rudolph T et al (2009) VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer 16:1219–1227CrossRefPubMed Schmitt AM, Schmid S, Rudolph T et al (2009) VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer 16:1219–1227CrossRefPubMed
26.
Zurück zum Zitat Singh S, Hallet J, Rowsell C et al (2014) Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol 40(11):1517–1522 Singh S, Hallet J, Rowsell C et al (2014) Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease. Eur J Surg Oncol 40(11):1517–1522
27.
Zurück zum Zitat Sipos B, Kloppel G (2005) Acinar cell carcinomas and pancreatoblastomas: related but not the same. Pathologe 26:37–40CrossRefPubMed Sipos B, Kloppel G (2005) Acinar cell carcinomas and pancreatoblastomas: related but not the same. Pathologe 26:37–40CrossRefPubMed
28.
Zurück zum Zitat Stefanoli M, La Rosa S, Sahnane N et al (2014) Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Neuroendocrinology 100:26–34CrossRefPubMed Stefanoli M, La Rosa S, Sahnane N et al (2014) Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Neuroendocrinology 100:26–34CrossRefPubMed
29.
Zurück zum Zitat Strosberg JR, Cheema A, Weber JM et al (2012) Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 256:321–325CrossRefPubMed Strosberg JR, Cheema A, Weber JM et al (2012) Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 256:321–325CrossRefPubMed
30.
Zurück zum Zitat Velayoudom-Cephise FL, Duvillard P, Foucan L et al (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20:649–657CrossRefPubMed Velayoudom-Cephise FL, Duvillard P, Foucan L et al (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20:649–657CrossRefPubMed
31.
32.
Zurück zum Zitat Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182CrossRefPubMed Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182CrossRefPubMed
34.
Zurück zum Zitat Yachida S, Vakiani E, White CM et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173–184CrossRefPubMedCentralPubMed Yachida S, Vakiani E, White CM et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173–184CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Zhang L, Smyrk TC, Oliveira AM et al (2009) KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 33:1562–1569CrossRefPubMed Zhang L, Smyrk TC, Oliveira AM et al (2009) KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 33:1562–1569CrossRefPubMed
36.
Zurück zum Zitat Zhao J, Moch H, Scheidweiler AF et al (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32:364–372CrossRefPubMed Zhao J, Moch H, Scheidweiler AF et al (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32:364–372CrossRefPubMed
37.
Zurück zum Zitat Zhou C, Dhall D, Nissen NN et al (2009) Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 38:941–946CrossRefPubMedCentralPubMed Zhou C, Dhall D, Nissen NN et al (2009) Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 38:941–946CrossRefPubMedCentralPubMed
Metadaten
Titel
Was ist neu in der Pathologie neuroendokriner Tumoren des Pankreas?
verfasst von
Prof. Dr. P. Komminoth
Prof. Dr. A. Perren
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Pathologie / Ausgabe 3/2015
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-015-0023-1

Weitere Artikel der Ausgabe 3/2015

Der Pathologe 3/2015 Zur Ausgabe

Schwerpunkt: Neuroendokrine Tumoren

Die C-Zellen der Schilddrüse und ihre Pathologie

Schwerpunkt: Neuroendokrine Tumoren

Pathologie der Nebenschilddrüse

Schwerpunkt: Neuroendokrine Tumoren

Neues aus der Tumorpathologie der Nebenniere

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.